Briefing documents show why the FDA should await more data on the ALS project, but will it bow to patient pressure?
March Pdufa dates are set for relatlimab as well as Akebia’s vadadustat, while Amylyx’s ALS drug heads for a panel.
Three of the top five buyouts of 2021 happened in the final quarter, and with biotech stocks hurting many hope that the flurry will continue.
2021 was a huge year for IPOs, with pure-play developers raising $14bn, but 2022 is likely to tell a different story.
Despite several recent late-stage failures, there is still a lot going on in the ALS pipeline.
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.